abiraterone,olaparib
astrazeneca,merck
['brca', 'crpc', '#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)', 'olaparib', 'propel']
#propel study confirms a strong os signal in mcrpc all-comers. is data on post-progression therapy (i.e n of brca+ pts in control arm receiving olaparib) needed to understand the results? #gu23
Medical Oncologist at the Hospital Provincial Castellón